E Coli Partnering 2007 2012 by krushnercelina

VIEWS: 4 PAGES: 4

E-coli Partnering 2007-2012 is intended to provide the reader with an in-depth understanding and access to e-coli trends and structure of deals entered into by leading companies worldwide.

More Info
									E-coli Partnering 2007-2012
Published : July 2012                No. of Pages : 100                 Price:US$995




The E-coli Partnering 2007-2012 report provides understanding and access to the e-coli partnering deals
and agreements entered into by the worlds leading healthcare companies.
Top e-coli deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type
The E-coli Partnering 2007-2012 provides understanding and access to the e-coli partnering deals and
agreements entered into by the worlds leading healthcare companies.
The report provides an analysis of e-coli partnering deals. The majority of deals are discovery or
development stage whereby the licensee obtains a right or an option right to license the licensors e-coli
technology. These deals tend to be multicomponent, starting with collaborative R&D, and
commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into
the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst
many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms
of how payments are triggered – contract documents provide this insight where press releases do not.
This data driven report contains over 30 links to online copies of actual e-coli deals and contract
documents as submitted to the Securities Exchange Commission by companies and their partners, where
available. Contract documents provide the answers to numerous questions about a prospective partner’s
flexibility on a wide range of important issues, many of which will have a significant impact on each party’s
ability to derive value from the deal.The initial chapters of this report provide an orientation of e-coli
partnering trends.

Report scope
E-coli Partnering 2007-2012 is intended to provide the reader with an in-depth understanding and access
to e-coli trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:
Trends in e-coli dealmaking in the biopharma industry since 2007
Access to summary headline, upfront, milestone and royalty data
The leading e-coli deals by value since 2007

E-coli Partnering 2007-2012 provides the reader with the following key benefits:
In-depth understanding of e-coli deal trends since 2007
Access to summary headline, upfront, milestone and royalty data
Insight into key deal terms included in contracts, where disclosed
Understand the key deal terms companies have agreed in deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

E-coli Partnering 2007-2012

Table Of contents

Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in e-coli partnering
2.1. Introduction
2.2. E-coli partnering over the years
2.3. Bigpharma e-coli dealmaking activity
2.4. E-coli partnering by deal type
2.5. E-coli partnering industry sector
2.6. E-coli partnering by stage of development
2.7. E-coli partnering by technology type
2.8. Disclosed financial deal terms for e-coli partnering
2.8.1 E-coli headline values
2.8.2 E-coli upfront payments
2.8.3 E-coli milestone payments
2.8.4 E-coli royalty rates
Chapter 3 – Leading e-coli deals
3.1. Introduction
3.2. Top e-coli deals by value
3.3. Top e-coli deals involving bigpharma
Chapter 4 – Dealmaking directory
4.1. Introduction
4.2. Company A-Z
4.3. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Termination
4.4. By industry sector
Academic
Bigpharma
Biotech
Drug delivery
Medical device
Diagnostic
Generic pharma
Government
Non-profit
Pharmaceutical
Research tools
Services
Specialty pharma
4.5. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
4.6. By technology type
Analysis
Animal models
Assays
Bioinformatics
Biological compounds
Biomarkers
Biomaterials
Cell culture
Cell therapy
Clinical testing
Diagnostic - companion
Devices
Diagnostics
Discovery tools
DNA probes
Drug delivery
Enabling technology
Epigenetics
Equipment
Facilities
Gene therapy
Genomics
Imaging
Industrial chemicals
In vitro models
Monoclonal antibodies
Nanotechnology
Oligonucleotide
Peptides
Personalised medicine
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Stem cells
Vaccines
Chapter 5 – Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking
Appendices
Appendix 1 – Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports

List of Figures

								
To top